Bempedoic Acid: First Approval

被引：67

作者：

Markham, Anthony ^{[1
]}

机构：

[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2020年 / 80卷 / 07期

关键词：

DENSITY-LIPOPROTEIN-CHOLESTEROL; ACTIVATED PROTEIN-KINASE; CITRATE LYASE; EFFICACY; ETC-1002; SAFETY; HYPERCHOLESTEROLEMIA;

D O I：

10.1007/s40265-020-01308-w

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Bempedoic acid is a non-statin antihyperlipidaemic drug being developed by Esperion Therapeutics for the treatment of hypercholesterolaemia. Based on positive findings in the phase III CLEAR clinical trial programme, bempedoic acid has been approved in the USA and in the EU as monotherapy (NEXLETOL(R) in the USA, Nilemdo(R) in the EU) and as a fixed-dose combination with ezetimibe (NEXLIZET(R) in the USA, Nustendi(R) in the EU). This article summarizes the milestones in the development of bempedoic acid leading to these first approvals.

引用

页码：747 / 753

页数：7

共 18 条

[1] Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy [J].

Ballantyne, Christie M. ;

Laufs, Ulrich ;

Ray, Kausik K. ;

Leiter, Lawrence A. ;

Bays, Harold E. ;

Goldberg, Anne C. ;

Stroes, Erik S. G. ;

MacDougall, Diane ;

Zhao, Xin ;

Catapano, Alberico L. .

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (06) :593-603

[2] Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study [J].

Ballantyne, Christie M. ;

Banach, Maciej ;

Mancini, G. B. John ;

Lepor, Norman E. ;

Hanselman, Jeffrey C. ;

Zhao, Xin ;

Leiter, Lawrence A. .

ATHEROSCLEROSIS, 2018, 277 :195-203

[3] Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia [J].

Ballantyne, Christie M. ;

Davidson, Michael H. ;

MacDougall, Diane E. ;

Bays, Harold E. ;

DiCarlo, Lorenzo A. ;

Rosenberg, Noah L. ;

Margulies, Janice ;

Newton, Roger S. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (13) :1154-1162

[4]

*ESP THER INC, 2020, NEXLETOL BEMP AC US

[5]

Esperion Therapeutics Inc, 2020, NEXLIZET BEMP AC EZ

[6]

European Medicines Agency, 2020, NIL BEMP AC EU SUMM

[7]

European Medicines Agency, 2020, M HIGHL PHARM RISK A

[8] Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial [J].

Goldberg, Anne C. ;

Leiter, Lawrence A. ;

Stroes, Erik S. G. ;

Baum, Seth J. ;

Hanselman, Jeffrey C. ;

Bloedon, LeAnne T. ;

Lalwani, Narendra D. ;

Patel, Pragna M. ;

Zhao, Xin ;

Duell, P. Barton .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (18) :1780-1788

[9] Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol-Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus [J].

Gutierrez, Maria J. ;

Rosenberg, Noah L. ;

MacDougall, Diane E. ;

Hanselman, Jeffrey C. ;

Margulies, Janice R. ;

Strange, Poul ;

Milad, Mark A. ;

McBride, Scott J. ;

Newton, Roger S. .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2014, 34 (03) :676-683

[10] Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial [J].

Lalwani, Narendra D. ;

Hanselman, Jeffrey C. ;

MacDougall, Diane E. ;

Sterling, Lulu R. ;

Cramer, Clay T. .

JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (04) :568-579

← 1 2 →